—Seizure clusters in patients with epilepsy have negative effects on quality of life, morbidity, and healthcare utilization. Being able to identify risk factors for seizure clusters could help ...

For most people with epilepsy, seizures can be completely controlled by taking daily medication. However, some people still experience seizures despite taking daily medication. If these seizures recur ...

If you have seizure clusters -- multiple seizures within a short time -- you or your doctor may notice that they're more likely to happen at certain times or in certain situations. For about 30% of ...

LOS ANGELES — The definition of seizure clusters varies significantly across epilepsy monitoring units (EMUs), according to a new survey of expert opinion. The findings should prompt the development ...

The US Food and Drug Administration (FDA) has approved diazepam nasal spray (Valtoco, Neurelis) in patients with epilepsy aged 6 and older for the acute treatment of intermittent, stereotypic episodes ...

A seizure typically is an event that ha-- could happen at any time. A seizure cluster is the recurrence of this event, one after another. And in between these two events, by definition, the patient ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

Neurelis announced the availability of Valtoco® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute ...

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ -- Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment of seizure ...

(BPT) - At just one day old, Spencer, born in Greenville, South Carolina, had his first seizure, a sudden, uncontrolled electrical disturbance in the brain that usually causes a change in behavior.

The product was approved in May based on data from the phase 3, placebo-controlled ARTEMIS 1 trial that evaluated the safety and efficacy of the intranasal benzodiazepine in 292 patients. Nayzilam ...